Quarter-Century Transformation of Oncology: Positron Emission Tomography for Patients with Breast Cancer

Gary A Ulaner; Sofia Carrilho Vaz; David Groheux

doi:10.1016/j.cpet.2023.12.002

Quarter-Century Transformation of Oncology: Positron Emission Tomography for Patients with Breast Cancer

PET Clin. 2024 Apr;19(2):147-162. doi: 10.1016/j.cpet.2023.12.002. Epub 2024 Jan 4.

Authors

Gary A Ulaner¹, Sofia Carrilho Vaz², David Groheux³

Affiliations

¹ Molecular Imaging and Therapy, Hoag Family Cancer Institute, Irvine, CA, USA; Departments of Radiology and Translational Genomics, University of Southern California, Los Angeles, CA, USA. Electronic address: [email protected].
² Nuclear Medicine-Radiopharmacology, Champalimaud Clinical Center, Champalimaud Foundation, Lisbon, Portugal; Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands.
³ Nuclear Department of Nuclear Medicine, Saint-Louis Hospital, Paris, France; Centre d'Imagerie Radio-Isotopique (CIRI), La Rochelle, France; University Paris-Diderot, INSERM U976, HIPI, Paris, France.

PMID: 38177052
DOI: 10.1016/j.cpet.2023.12.002

Abstract

PET radiotracers have become indispensable in the care of patients with breast cancer. ¹⁸F-fluorodeoxyglucose has become the preferred method of many oncologists for systemic staging of breast cancer at initial diagnosis, detecting recurrent disease, and for measuring treatment response after therapy. ¹⁸F-Sodium Fluoride is valuable for detection of osseous metastases. ¹⁸F-fluoroestradiol is now FDA-approved with multiple appropriate clinical uses. There are multiple PET radiotracers in clinical trials, which may add utility of PET imaging for patients with breast cancer in the future. This article will describe the advances during the last quarter century in PET for patients with breast cancer.

Keywords: (18)F-FDG; (18)F-FES; (18)F-NaF; Breast cancer; Position emission tomography.

Publication types

Review

MeSH terms

Bone Neoplasms* / diagnostic imaging
Bone Neoplasms* / secondary
Breast Neoplasms* / diagnostic imaging
Breast Neoplasms* / pathology
Female
Fluorodeoxyglucose F18
Humans
Positron Emission Tomography Computed Tomography / methods
Positron-Emission Tomography

Substances

Fluorodeoxyglucose F18